| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.0096 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | -0.0095 | 0.8 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.8 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |